Pride, lasten transhoidot ja Setan aktivismi (Riittakerttu Kaltiala) | Puheenaihe 685

Main arguments and claims in the discussion

• Riitta Kärtty Kalteala argues that current “Seta / Pride”-linked activism undermines medical research and clinical decision-making in Finland.

  • She claims Pride demonstrations included insulting, derogatory, and even threatening messaging targeted at doctors and her research group.
  • She says this rhetoric aims to discourage scientific work, publication, and public dissemination of research.

• She criticizes a preferred treatment principle she associates with this activism: gender-affirming/“gender identity–modifying” treatments should be provided based on self-determined choice, rather than through medical assessment (e.g., diagnosis, stability of identity, mental health evaluation, and clinical indications).

  • Her position is that healthcare generally acts on best available evidence, diagnosis, suitability, timing, and expected health benefits—not simply expressed desire.

Medical framing: terminology and what “gender anxiety/dysphoria” means

• She emphasizes that terminology is contested and shifting, which she says makes public discussion confusing.
• She distinguishes between:
  • Stable, long-term identity experiences
  • Gender-related distress/anxiety that may occur during development
• She argues that not everyone who has incongruence between biological sex and experienced gender is necessarily distressed or necessarily wants medical physical interventions.

“What science says” (as presented by her)

• Cause is unknown: she says research has not found a complete or conclusive explanation for why people experience gender incongruence.
• Potential benefit for some adults exists: she acknowledges that some people may experience improved wellbeing after physical gender-related treatments, while also stressing uncertainty.
• Adolescence is a special case: she argues identity development continues in youth, so decisions about irreversible interventions are high-stakes.
• Developmental course may often improve without medical transition: she cites research suggesting that a significant portion of youth who experience gender dissatisfaction/anxiety in early adolescence later desist, with only a small minority showing increasing dissatisfaction into young adulthood.
• Uncertainty about persistence: she argues it is difficult to reliably distinguish temporary distress from persistent needs, especially in real-world clinical settings.

Critique of puberty blockers and gender-affirming hormones for minors (“blogger treatment” / puberty blockers)

• She argues the “pause puberty” logic is wrong: in her description, many patients proceed from blockers to cross-sex hormones, rather than using blockers only temporarily.
• Risks she highlights:
  • Potential cognitive development effects (she claims risk is not sufficiently studied)
  • Infertility (she presents it as a major concern)
  • Potential permanent impairment of sexual function if decisions are made early
  • Some hormone effects are rapidly irreversible (e.g., voice change and other physical traits)
  • If surgery is involved (she notes it is not done for minors in Finland), it cannot be reversed

Mental health, suicidality, and “benefits” claims

• She claims there is no research evidence that these physical treatments reduce suicidality.
• She argues suicide risk is better explained by co-occurring serious psychiatric disorders, so suicide prevention should focus on treating mental health conditions, not on rushing into physical interventions.
• She criticizes claims that mental health problems are caused only by stigma/discrimination and would “resolve” once the body is modified; she says systematic reviews have not shown psychiatric problems disappearing as a result of these treatments.

Psychiatric comorbidity and assessment

• She states that many adolescents seeking gender-identity clinics for physical treatment have serious psychiatric illnesses, which she says can complicate assessment of identity development.
• Her approach: treat psychiatric disorders first (as in child psychiatry), and only consider physical interventions if appropriate and safe.

Autism and correlations (as discussed by her)

• She says autism spectrum disorder/traits appear overrepresented among youth referred for gender-identity assessment.
• She argues causal explanations are unclear, and hypotheses are debated.

Comparison to eating disorders (anorexia) and “identity communities”

• She draws an analogy to body-image–related conditions and rejects the idea that evidence strongly supports simplistic comparisons.
• She says research quality on the relationship between gender dysphoria/anxiety and eating disorders is poor, but she claims her own research group has found that starting gender-related treatments does not eliminate existing eating disorders, and that eating disorders can also emerge after treatment begins.

Pride/Seta activism and “international standards”

• She argues that WPAS/WPATH-type recommendations (e.g., “Standards of Care”) are:
  • heavily influenced by advocacy groups rather than neutral professional evidence standards
  • more grounded in consensus and political goals than in demonstrated safety/benefit for minors
  • her claim is that guidance for minors would allow pathways she considers ethically and medically problematic, including potential surgical options and weakening/removal of age limits
• She argues Finland’s approach has been more conservative/cautious due to:
  • systematic reviews
  • an emphasis on evidence and safety
  • an expectation of medical benefit without harm

Pride as a broader political/ethical dispute

• She questions whether organizations should tolerate slogans she views as targeting and threatening individual clinicians, arguing this conflicts with the values of institutional partners and medical ethics.
• She claims this kind of rhetoric discourages researchers and may harm future scientific participation.

Regret/detransition and withdrawal rates (figures she cites)

• She describes regret/detransition estimates as historically uncertain, depending on how clinics report outcomes.
• She says more recent data suggest higher rates of stopping hormones than older assumptions (she cites “modern era” estimates such as 30–40% leaving hormone treatment in some contexts).
• She claims Finnish registry data show ~8% stopping or switching away from cross-sex hormones over a longer period.
• She also argues that “identity reversal”/relief can occur in a substantial portion during follow-up in some systems (she mentions figures like “in at least half” in 5-year follow-up contexts, as described by her).
• She argues that critics of her perspective say regret is downplayed, while she frames these uncertainties as reasons for caution with minors.

Presenters / contributors

• Riitta Kärtty Kalteala — professor of adolescent psychiatry; chief physician; clinical/scientific work related to adolescent gender identity assessments and research.
• Video host / interviewer — not explicitly named in the provided subtitles (a greeting/introductions occur, but the interviewer’s name is not given).